IntelliCell BioSciences Announces It Will File an IND for
Osteoarthritis of the Knee in Conjunction With the Andrews's
Research and Educational Foundation
NEW YORK, NY--(Marketwired - Mar 17, 2014) - IntelliCell
Biosciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a
regenerative medicine company utilizing adult autologous vascular
cells (SVCs) derived from the blood vessels found in adipose
tissue, announced today that it has signed consulting agreements
with Dr Adam Anz and Dr Josh Hackel of the Andrews's Research and
Education Foundation (AREF) in Gulf Breeze,
Florida. Intellicell will be filing an IND for the treatment
of osteoarthritis of knee lead by Dr. James Andrews and conducted
by Drs. Anz and Hackel for its Stromal Vascular Fraction Cells
(SVFC).
IntelliCell's Chief Executive Officer, Dr. Steven Victor,
remarked, "I am excited that the company will be filing its first
IND for osteoarthritis of the knee and has the honor to be working
with Dr. Andrews, Dr. Anz and Dr. Hackel. They are the some of
the most prominent sports medicine physicians in the
company. Dr. Anz and Dr. Hackel bring their vast knowledge and
experience in stem cells to this project. With this distinguished
group of doctors on board we will be able to advance the research
and science of the SVF cellular product in the fields of orthopedic
and sports medicine."
As said by Dr. Adam Anz, "Dr. Victor, through Intellicell
Biosciences, has been a pioneer in the clinical application of stem
cell therapy in the United States. His interactions with the
FDA have helped us understand the current regulatory status, and he
has a practice, which recently has passed their scrutiny. At
the Andrews Research and Education Institute, we look forward to
collaborating with him and to applying his technology in a
compliant fashion. Working together we will produce evidence
about the value of stem cell therapy for the treatment of joint
injuries and degeneration, which will help us treat our patients
better."
According to Dr. Josh Hackel, "We have recognized IntelliCell
BioSciences as a forward thinking company and we are excited to
continue FDA compliant research in this area as it relates to
sports medicine and the treatment of our patients. It will be
research like this at the Andrews Research and Education Institute
in collaboration with IntelliCell BioSciences that will further our
understanding and improve our management of sports medicine
injuries."
About IntelliCell Biosciences IntelliCell is a pioneering
regenerative medicine company focused on the expanding regenerative
medical markets using adult autologous stromal vascular fraction
cells (SVFCs) derived from the blood vessels in the adult adipose
tissue. IntelliCell Biosciences has developed its own patented
technology and protocol to separate adult autologous vascular cells
from adipose tissue without the use of enzymes. IntelliCell will
also be seeking to develop technology-licensing agreements with
technology developers, universities, and international business
entities.
About Dr. James Andrews Dr. James Andrews is internationally
known and recognized for his scientific and clinical research
contributions in knee, shoulder and elbow injuries, as well as his
skill as an orthopedic surgeon. Dr. Andrews is a founding partner
and medical director for the Andrews Institute in Gulf Breeze,
Florida. In addition, he is a founding member of the American
Sports Medicine Institute (ASMI).
Dr. Andrews has been the mentor for more than 250
orthopedic/sports medicine fellows and more than 45 primary care
sports medicine fellows. Involved in education and research in
sports medicine and orthopedic surgery, he has made major
presentations on every continent, and has authored numerous
scientific articles and books.
About Dr. Adam Anz Adam Williams Anz, M.D., is a fellowship
trained orthopedic surgeon who specializes in sports related
injuries, specifically focusing on complex knee surgery, hip
arthroscopy, and innovative stem cell treatments. He has many
peer-reviewed publications and presentations with a special
interest in cartilage regeneration. His main goal is to keep
patients of all ages as active as possible in the least invasive
way possible.
He completed his orthopedic surgery residency training at Wake
Forest University in Winston-Salem, North Carolina where he worked
extensively with the Wake Forest Demon Deacons Football team. After
residency, he completed a sports fellowship at the world-renowned
Steadman Clinic in Vail, Colorado where he learned complex knee
surgery from the famed Drs. Steadman and Laprade and hip
arthroscopy from Dr. Philippon.
Dr. Anz has numerous orthopedic journal publications and a
strong interest in research with projects including the use of CT
3-D reconstruction for subtle hip deformities and a biomechanical
project involving MLB pitchers with elbow injury. Dr. Anz's
strongest research interest is in cartilage regeneration. During
residency he spent 3 weeks in Malaysia with Dr. Khay Yong Saw, an
orthopedic surgeon who has pioneered a method to regenerate
cartilage using a patient's own stem cells. He returned to Malaysia
after his time at the Steadman Clinic for a stem cell fellowship
and to work on preparing an application to the FDA in order to
apply this cutting edge stem cell technology within the United
States.
About Dr. Josh Hackel Dr. Joshua Hackel, a sports medicine
physician, specializes in the prevention, diagnosis, and
conservative management of musculoskeletal injuries utilizing the
latest medical techniques for anyone who is injured on the job or
at home, a weekend warrior, professional, high school or
recreational athlete.
Following his residency in 2003 in Family Practice at Columbus
Regional Medical Center in Columbus, GA, Dr. Hackel accepted a
fellowship at the American Sports Medicine Institute (ASMI) in
Primary Care Sports Medicine under the direction of orthopedic
surgeon Dr. James R. Andrews. Upon completion of the fellowship he
was invited to become a member of the Andrews Orthopedic &
Sports Medicine Center in Gulf Breeze, FL.
Dr. Hackel treats acute and chronic musculoskeletal injuries
such as joint sprains, strains, knee, hip, elbow, foot, ankle and
shoulder injuries, fractures and stress fractures,
arthritis/degenerative joint disease, athletes with chronic or
acute illnesses, and nutrition.
Dr. Hackel has a multitude of team physician experience in many
different sport and recreational arenas. These include team
physician for the University of West Florida, Troy University
football, Birmingham Barons baseball (AA affiliate of the Chicago
White Sox), Birmingham Power of the WNBA, Arena Football's
Birmingham Steeldogs, Southeastern Conference (SEC) womenÂ's
basketball tournament, Mercedes Olympic Marathon, and the Medical
Director for the Pensacola Marathon.
Dr. Hackel practices in Gulf Breeze at the Andrews Orthopedic
& Sports Medicine Center and serves as an Associate Clinical
Professor of Medicine at Florida State School of Medicine.
Forward-Looking Statements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact: IntelliCell BioSciences, Inc. Investor Relations Anna
Rhodes Email Contact (646) 576-8308